PMID- 23078638
OWN - NLM
STAT- MEDLINE
DCOM- 20130802
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Mar
TI  - Exenatide once weekly improved glycaemic control, cardiometabolic risk factors 
      and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, 
      over 52 weeks.
PG  - 264-71
LID - 10.1111/dom.12026 [doi]
AB  - AIMS: Type 2 diabetes mellitus (T2DM) is often associated with cardiovascular 
      (CV) risk factors such as obesity, hypertension and dyslipidemia. The objective 
      of this analysis was to evaluate potential effects of exenatide once weekly 
      (ExQW), a GLP-1 receptor agonist, on glycaemic control and CV risk factors. 
      METHODS: This analysis included 675 Intent-to-Treat patients with T2DM [baseline 
      (mean +/- SD) HbA1c, 8.1 +/- 1.2%; fasting blood glucose (FBG), 166 +/- 48 mg/dl; 
      weight, 94.3 +/- 19.4 kg; systolic/diastolic blood pressure (SBP/DBP), 129 +/- 15/78 
      +/- 9 mm Hg; total cholesterol, 178.5 +/- 41.9 mg/dl; low-density lipoprotein (LDL), 
      100.1 +/- 35.0 mg/dl; high-density lipoprotein (HDL), 44.5 +/- 11.6 mg/dl; 
      triglycerides, 155.6 +/- 3.3 mg/dl; alanine aminotransferase (ALT), 32.1 +/- 19.5 
      U/l] treated with diet and exercise alone or in combination with metformin, 
      sulfonylurea, and/or thiazolidinedione who received 52 weeks of ExQW in four 
      clinical trials. RESULTS: At 52 weeks, ExQW significantly improved HbA1c [mean 
      (SE) change from baseline, -1.3 (0.05)%], FBG [-36.3 (2.02) mg/dl], body weight 
      [-2.6 (0.19) kg], SBP/DBP [-3.6 (0.56) mm Hg/-1.2 (0.34) mm Hg], total 
      cholesterol, -4.4 (1.33) mg/dl; LDL, -2.6 (1.08) mg/dl; HDL, 1.1 (0.31) mg/dl; 
      triglycerides, -7 (1.6)%], and ALT [-4.3 (0.71) IU/l] concentrations, with 
      greater improvements in patients with elevated analyte levels at baseline. 
      Improvements were observed across a range of background antihyperglycaemia 
      therapies. Of patients completing 52 weeks, 19% achieved the composite American 
      Diabetes Association goal (HbA1c < 7.0%, BP < 130/80 mm Hg, LDL < 100 mg/dl), 
      compared to 1% at baseline. Nearly half (48%) achieved HbA1c < 7.0% without 
      weight gain or major/minor hypoglycaemia. Nausea was the most frequent adverse 
      event and was predominantly mild. Hypoglycaemia was infrequent, and more common 
      with a sulfonylurea. CONCLUSIONS: With 52 weeks of ExQW, patients experienced 
      sustained improvements in glycaemic control and CV risk factors, with an 
      increased likelihood of achieving both a clinically relevant composite outcome 
      (HbA1c < 7% without weight gain or increased risk of hypoglycaemia) and a 
      composite of key therapeutic goals (HbA1c < 7%, BP < 130/80 mm Hg, LDL < 100 
      mg/dl).
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Bergenstal, R M
AU  - Bergenstal RM
AD  - International Diabetes Center, Minneapolis, MN, USA. 
      Richard.Bergenstal@ParkNicollet.com
FAU - Li, Y
AU  - Li Y
FAU - Porter, T K Booker
AU  - Porter TK
FAU - Weaver, C
AU  - Weaver C
FAU - Han, J
AU  - Han J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121112
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Venoms)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Blood Glucose/*drug effects/metabolism
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Diabetic Angiopathies/blood/*prevention & control
MH  - Drug Administration Schedule
MH  - Exenatide
MH  - Female
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Male
MH  - Medication Adherence
MH  - Metformin/administration & dosage/pharmacology
MH  - Middle Aged
MH  - Peptides/administration & dosage/*pharmacology
MH  - Risk Factors
MH  - Sulfonylurea Compounds/administration & dosage/pharmacology
MH  - Time Factors
MH  - Venoms/administration & dosage/*pharmacology
MH  - Weight Gain
PMC - PMC3593159
EDAT- 2012/10/20 06:00
MHDA- 2013/08/03 06:00
CRDT- 2012/10/20 06:00
PHST- 2012/05/11 00:00 [received]
PHST- 2012/06/13 00:00 [revised]
PHST- 2012/10/01 00:00 [accepted]
PHST- 2012/10/20 06:00 [entrez]
PHST- 2012/10/20 06:00 [pubmed]
PHST- 2013/08/03 06:00 [medline]
AID - 10.1111/dom.12026 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Mar;15(3):264-71. doi: 10.1111/dom.12026. Epub 2012 Nov 
      12.